FI4114390T3 - Menetelmiä fabryn taudin hoitamiseksi potilaissa, joilla on mutaatio gla-geenissä - Google Patents

Menetelmiä fabryn taudin hoitamiseksi potilaissa, joilla on mutaatio gla-geenissä Download PDF

Info

Publication number
FI4114390T3
FI4114390T3 FIEP21715035.8T FI21715035T FI4114390T3 FI 4114390 T3 FI4114390 T3 FI 4114390T3 FI 21715035 T FI21715035 T FI 21715035T FI 4114390 T3 FI4114390 T3 FI 4114390T3
Authority
FI
Finland
Prior art keywords
migalastat
salt
patient
use according
administered
Prior art date
Application number
FIEP21715035.8T
Other languages
English (en)
Finnish (fi)
Inventor
Elfrida Benjamin
Xiaoyang Wu
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75267607&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI4114390(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Application granted granted Critical
Publication of FI4114390T3 publication Critical patent/FI4114390T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FIEP21715035.8T 2020-03-06 2021-03-05 Menetelmiä fabryn taudin hoitamiseksi potilaissa, joilla on mutaatio gla-geenissä FI4114390T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062986297P 2020-03-06 2020-03-06
PCT/US2021/020984 WO2021178737A1 (en) 2020-03-06 2021-03-05 Methods of treating fabry disease in patients having a mutation in the gla gene

Publications (1)

Publication Number Publication Date
FI4114390T3 true FI4114390T3 (fi) 2025-03-07

Family

ID=75267607

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP21715035.8T FI4114390T3 (fi) 2020-03-06 2021-03-05 Menetelmiä fabryn taudin hoitamiseksi potilaissa, joilla on mutaatio gla-geenissä

Country Status (25)

Country Link
US (1) US20230136297A1 (cg-RX-API-DMAC7.html)
EP (2) EP4527454A3 (cg-RX-API-DMAC7.html)
JP (2) JP7749572B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220152547A (cg-RX-API-DMAC7.html)
CN (1) CN115427040A (cg-RX-API-DMAC7.html)
AR (1) AR122390A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021230371A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022017881A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170718A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002423A1 (cg-RX-API-DMAC7.html)
DK (1) DK4114390T3 (cg-RX-API-DMAC7.html)
ES (1) ES3013813T3 (cg-RX-API-DMAC7.html)
FI (1) FI4114390T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250179T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070116T2 (cg-RX-API-DMAC7.html)
IL (1) IL296221A (cg-RX-API-DMAC7.html)
LT (1) LT4114390T (cg-RX-API-DMAC7.html)
MX (1) MX2022011030A (cg-RX-API-DMAC7.html)
PL (1) PL4114390T3 (cg-RX-API-DMAC7.html)
PT (1) PT4114390T (cg-RX-API-DMAC7.html)
RS (1) RS66530B1 (cg-RX-API-DMAC7.html)
SI (1) SI4114390T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500072T1 (cg-RX-API-DMAC7.html)
TW (1) TW202146020A (cg-RX-API-DMAC7.html)
WO (1) WO2021178737A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3840753T (lt) * 2018-08-20 2024-11-11 Amicus Therapeutics, Inc. Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
WO2009102895A2 (en) * 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
WO2012125402A2 (en) * 2011-03-11 2012-09-20 Amicus Therapeutics, Inc. Dosing regimens for the treatment of fabry disease
US11034946B2 (en) * 2017-10-05 2021-06-15 Research Foundation Of The City University Of New York Glycosylation independent proteins

Also Published As

Publication number Publication date
HUE070116T2 (hu) 2025-05-28
PL4114390T3 (pl) 2025-06-23
TW202146020A (zh) 2021-12-16
RS66530B1 (sr) 2025-03-31
ES3013813T3 (en) 2025-04-15
SI4114390T1 (sl) 2025-03-31
LT4114390T (lt) 2025-02-10
HRP20250179T1 (hr) 2025-04-11
EP4527454A2 (en) 2025-03-26
US20230136297A1 (en) 2023-05-04
AU2021230371A1 (en) 2022-09-29
JP2026016375A (ja) 2026-02-03
AR122390A1 (es) 2022-09-07
EP4114390B1 (en) 2024-12-04
SMT202500072T1 (it) 2025-03-12
EP4114390A1 (en) 2023-01-11
DK4114390T3 (da) 2025-02-24
CN115427040A (zh) 2022-12-02
JP7749572B2 (ja) 2025-10-06
KR20220152547A (ko) 2022-11-16
PT4114390T (pt) 2025-02-24
MX2022011030A (es) 2022-12-13
CL2022002423A1 (es) 2023-05-05
EP4527454A3 (en) 2025-09-24
WO2021178737A1 (en) 2021-09-10
BR112022017881A2 (pt) 2022-12-06
JP2023516753A (ja) 2023-04-20
IL296221A (en) 2022-11-01
CA3170718A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
FI3840753T3 (fi) Migalastaatti käytettäväksi fabryn taudin hoitomenetelmissä potilailla joilla on gla-geenin mutaatio
US9980927B2 (en) Use of tapentadol for inhibiting and/or treating depression and anxiety
FI3457135T3 (fi) Fabryn taudin hoitovaihtoehtoja
US6596756B1 (en) Treatment of fibromyalgia
JP2021535107A5 (cg-RX-API-DMAC7.html)
JP6411680B1 (ja) Lsd1阻害剤を用いて多発性硬化症を処置する方法
KR20200105980A (ko) 근위축성 측색경화증의 치료 또는 병세 진전 억제를 위한 약제
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2023523706A5 (cg-RX-API-DMAC7.html)
Schutz et al. Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat
HRP20250179T1 (hr) Postupci liječenja fabrijeve bolesti kod pacijenta s mutacijom gla gena
JP2023516753A5 (cg-RX-API-DMAC7.html)
MX2023003258A (es) Tratamiento de enfermedades mediadas por nf-kb.
DK0839137T3 (da) Aromatiske carboxylsyrediamider med antigastrinvirkning, fremgangsmåde til deres fremstilling samt deres anvendelse som lægemidler
ES3034261T3 (en) Amiselimod for use in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome
JP3718849B2 (ja) 抗マラリア剤
ROBINSON SYNCOPE, CONVULSIONS AND THE UNCONSCIOUS STATE: RELATION TO THE HYPERACTIVE CAROTID SINUS REFLEX
CN105311387B (zh) 复方手参丸在制备治疗原发性震颤药物中的应用
TWI533869B (zh) 蒽醌[2,1-c][1,2,5]噻二唑-6,11-二酮化合物緩解疼痛的應用
CN1738626A (zh) 含有桂利嗪和茶苯海明的抗眩晕的组合制剂
RU2564907C1 (ru) Способ лечения больных красным плоским лишаем
JP5856613B2 (ja) 過敏性腸症候群の治療において使用するためのタペンタドール
US6479547B1 (en) Method of treating an infection by enhancing the effectiveness of the human immune system
US20070054940A1 (en) Remedy for down's syndrome
TW202313017A (zh) 治療自發性震顫的方法